Pasithea Therapeutics (KTTA) EBIT (2021 - 2026)
Pasithea Therapeutics (KTTA) posted EBIT of -$4.9 million for Q1 2026, up 52.45% sequentially from -$10.3 million in Q4 2025, and down 32.51% YoY from -$7.2 million in Q1 2025.
Pasithea Therapeutics (KTTA) EBIT (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported EBIT for 6 years, with the latest figure at -$4.9 million in Q1 2026.
- Quarterly EBIT fell 32.51% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.1 million (down 58.78% YoY) and the FY2025 annual result came in at -$20.9 million, down 46.37% from the prior year.
- EBIT grew to -$4.9 million in Q1 2026 per KTTA's latest filing, from -$10.3 million in the prior quarter.
- Over five years, EBIT peaked at -$2.4 million in Q1 2022 and troughed at -$10.3 million in Q4 2025.
- A 5-year average of -$4.2 million and a median of -$3.8 million in 2025 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2024: EBIT plunged 382.58% in 2022, then surged 36.69% in 2024.
- Over 5 years, EBIT stood at -$5.1 million in 2022, then fell by 1.34% to -$5.1 million in 2023, then soared by 36.69% to -$3.3 million in 2024, then plunged by 214.65% to -$10.3 million in 2025, then soared by 52.45% to -$4.9 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$4.9 million, -$10.3 million, and -$3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Pasithea Therapeutics | 15.13 Mn | 15.13 Mn | - | -5.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.88 Mn |
| Dec 31, 2025 | -10.26 Mn |
| Sep 30, 2025 | -3.11 Mn |
| Jun 30, 2025 | -3.81 Mn |
| Mar 31, 2025 | -3.68 Mn |
| Dec 31, 2024 | -3.26 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -3.95 Mn |
| Mar 31, 2024 | -4.04 Mn |
| Dec 31, 2023 | -5.15 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | -3.83 Mn |
| Mar 31, 2023 | -3.21 Mn |
| Dec 31, 2022 | -5.08 Mn |
| Sep 30, 2022 | -4.25 Mn |
| Jun 30, 2022 | -3.51 Mn |
| Mar 31, 2022 | -2.40 Mn |
| Dec 31, 2021 | -1.96 Mn |
| Sep 30, 2021 | -1.27 Mn |
| Jun 30, 2021 | -727,947.00 |